Wockhardt's Chikalthana plant gets GMP certificate from UKMHRA
New Delhi: In a major relief to drug firm Wockhardt, its Chikalthana plant at Aurangabad in Maharashtra has received a good manufacturing practice (GMP) certificate from the UK health regulator after an inspection."The company has undergone recently an inspection at its L1-Chikalthana, Aurangabad manufacturing facility by UK MHRA and has received a communication confirming the closure of...
Login or Register to read the full article
New Delhi: In a major relief to drug firm Wockhardt, its Chikalthana plant at Aurangabad in Maharashtra has received a good manufacturing practice (GMP) certificate from the UK health regulator after an inspection.
"The company has undergone recently an inspection at its L1-Chikalthana, Aurangabad manufacturing facility by UK MHRA and has received a communication confirming the closure of the inspection and issuance of an unrestricted GMP certificate", Wockhardt said in a filing to BSE.
In a filing to the bourses in October this year, Wockhardt had said United Kingdom Medicines and Healthcare Products Regulatory Agency (UKMHRA) had completed inspection of its Chikalthana plant without issuing any critical observations on the facility.
The UK regulator had in October 2013 withdrawn the GMP certificate to the Chikalthana plant and had also initiated recall of five prescription medicines from there.
"The company has undergone recently an inspection at its L1-Chikalthana, Aurangabad manufacturing facility by UK MHRA and has received a communication confirming the closure of the inspection and issuance of an unrestricted GMP certificate", Wockhardt said in a filing to BSE.
In a filing to the bourses in October this year, Wockhardt had said United Kingdom Medicines and Healthcare Products Regulatory Agency (UKMHRA) had completed inspection of its Chikalthana plant without issuing any critical observations on the facility.
The UK regulator had in October 2013 withdrawn the GMP certificate to the Chikalthana plant and had also initiated recall of five prescription medicines from there.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd